Comparative Pharmacology
Head-to-head clinical analysis: DECADRON versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON versus TEXACORT.
DECADRON vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor and modulating gene expression to produce anti-inflammatory and immunosuppressive effects. It also suppresses adrenal function by inhibiting ACTH secretion.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
0.75-9 mg/day orally in divided doses every 6-12 hours; or 0.5-9 mg/day IM/IV in divided doses every 12 hours for acute conditions; for cerebral edema, IV loading dose of 10 mg followed by 4 mg IM/IV every 6 hours.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal half-life: 3-4 hours (plasma); biological half-life: 36-54 hours (due to intracellular receptor binding); clinical context: duration of HPA axis suppression longer than plasma half-life
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal (65-80% as 17-hydroxycorticosteroids and 20-hydroxycorticosteroids after hepatic metabolism); biliary/fecal (minor, <10%)
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid